 |
|
 -Adrenergic Blocking Agents in Heart Failure
Benefits of Vasodilating and Nonvasodilating Agents According to Patients' Characteristics: A Meta-analysis of Clinical Trials
Sara Bonet, MD;
Antònia Agustí, MD;
Josep M. Arnau, MD;
Xavier Vidal, MD;
Eduard Diogène, MD;
Enrique Galve, MD;
Joan-Ramon Laporte, MD
Arch Intern Med. 2000;160:621-627.
Background In patients with heart failure,  -adrenergic blocking agents reduce overall and cardiovascular mortality. This meta-analysis aimed at clarifying their effect on sudden death, the magnitude of their benefit according to the cause of heart failure, and whether there is any difference between vasodilating and nonvasodilating agents.
Methods Randomized, clinical trials were included if they evaluated a -adrenergic blocking agent without intrinsic sympathomimetic activity, included a control group receiving placebo or standard treatment, evaluated mortality on an intention-to-treat basis, and lasted at least 8 weeks.
Results Twenty-one trials with 5849 patients (3130 receiving -blockers) were included. Median length of treatment was 6 months. Most patients had mild or moderate heart failure and were treated with angiotensin-converting enzyme inhibitors, diuretics, and digitalis. The -blockers significantly reduced overall mortality, cardiovascular mortality, and mortality due to pump failure and sudden death by 34% to 39%. The decrease in overall mortality in patients with ischemic heart disease (IHD) (30%) was no different from that among patients with non-IHD (26%) (P=.08). The reduction in overall mortality was greater with vasodilating than with nonvasodilating agents (45% vs 27%; P=.007), particularly in patients without IHD (62%), compared with those with IHD (22%; P=.03).
Conclusions In patients with heart failure, -blockers reduce total and cardiovascular mortality at the expense of a decrease in mortality due to pump failure and sudden death. The magnitude of the benefit is similar in patients with IHD and in those with non-IHD. Vasodilating -blockers have a greater effect on overall mortality than nonvasodilating agents, particularly in patients with non-IHD.
From the Fundació Institut Català de Farmacologia, Service of Clinical Pharmacology, Department of Pharmacology and Therapeutics (Drs Bonet, Agustí, Arnau, Vidal, Diogène, and Laporte), and the Service of Cardiology (Dr Galve), Hospitals Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTER
-Blockers in Congestive Heart Failure: Is There a Difference Between Classes?
Brian Stello, Sara Bonet, Antònia Agustí, Josep Maria Arnau, Xavier Vidal, Eduard Diogène, Enrique Galve, and Joan-Ramon Laporte
Arch Intern Med. 2000;160(19):3005-3006.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2000;160(5):718-719.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Ischemic mitral regurgitation: mechanisms and echocardiographic classification
Agricola et al.
Eur J Echocardiogr 2008;9:207-221.
ABSTRACT
| FULL TEXT
European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts)
Authors/Task Force Members et al.
Eur Heart J 2007;28:2375-2414.
FULL TEXT
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Authors/Task Force Members: et al.
Eur Heart J 2007;0:ehm236v1-75.
FULL TEXT
Effect of beta-blocker therapy on functional status in patients with heart failure -- A meta-analysis
Abdulla et al.
Eur J Heart Fail 2006;8:522-531.
ABSTRACT
| FULL TEXT
Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction
Wu et al.
J Am Coll Cardiol 2005;45:381-387.
ABSTRACT
| FULL TEXT
A Practical and Evidence-Based Approach to Cardiovascular Disease Risk Reduction
Gluckman et al.
Arch Intern Med 2004;164:1490-1500.
ABSTRACT
| FULL TEXT
Beta-blocker benefit according to severity of heart failure
Bouzamondo et al.
Eur J Heart Fail 2003;5:281-289.
ABSTRACT
| FULL TEXT
Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure
Shibata et al.
Eur J Heart Fail 2001;3:351-357.
ABSTRACT
| FULL TEXT
Intercurrent drug therapy and perioperative cardiovascular mortality in elective and urgent/emergency surgical patients{{dagger}}
Sear et al.
Br J Anaesth 2001;86:506-512.
ABSTRACT
| FULL TEXT
{beta}-Blockers in Congestive Heart Failure: Is There a Difference Between Classes?
Stello et al.
Arch Intern Med 2000;160:3005-3006.
FULL TEXT
|
